drugset / Trial / NCT07808827
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (JS203-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Timeline
- Start
- 2026-09-24
- Primary completion
- 2028-11-30
- Completion
- 2030-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | — |
| Comparator | Rituximab | Monoclonal antibody | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |